Abstract
Background: This review focuses on the treatment of pulmonary arterial hypertension (PAH) with selexipag and compares its drug-related therapeutic effects with those of prostacyclin analogues.
Methods: We searched the relevant literature and summarized the current clinical trials concerning selexipag and PAH.
Results: With only few cases per million, PAH is a rare disease, but when untreated it can be life-threatening. PAH is linked to elevated levels of endothelin (ET-1) and decreased levels of nitric oxide (NO) and prostacyclin (PGI2). PAH-specific therapeutic approaches concentrate on these characteristics with drugs targeting the endothelin- receptor (e.g. bosentan), phosphodiesterase-5 (e.g. sildenafil) or the prostacyclin-receptor (e.g. treprostinil). Recently, the new drug selexipag acting as a non-prostanoid IP2-receptor agonist has been approved for PAH therapy. The active form of selexipag (ACT-333679) was designed by the help of a medicinal chemistry program and it was further modified by replacing the terminal carboxyl group with an N-acylsulfonamide group to form the more stable oral drug, selexipag. Selexipag has a high selectivity for the IP2-receptor and differs from conventional prostacyclin analogues in its chemical structure. In the GRIPHON trial selexipag was demonstrated to significantly improve the primary composite endpoint of death or complications related to PAH (hazard ratio 0.6, 99% confidence interval, 0.46 to 0.78; P < 0.001) as well as exercise capacity in the form of the 6-minute walk distance (12.0 m treatment effect, 99% confidence interval, 1 to 24; P = 0.003). However, no significant reduction in all-cause mortality was achieved. Selexipag has also shown promising results in combination therapy with phosphodiesterase-5 inhibitors (PDE-5i) and/or endothelin receptor antagonists (ERA). The most common adverse effects (AEs), associated with selexipag, are headache, diarrhea, jaw pain, and nausea. Nevertheless, Selexipag was generally well tolerated during the GRIPHON trial.
Conclusions: Selexipag is a valuable addition to PAH therapeutics especially by reducing the PAH-related hospitalizations and thus improving quality of life in PAH patients.
Keywords: Pulmonary arterial hypertension, clinical trials, non-prostanoid IP2-receptor agonist, selexipag, prostacyclin analogues, headache.
Current Pharmaceutical Design
Title:A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension
Volume: 23 Issue: 34
Author(s): Louise M. Sorensen, Markus Wehland, Marcus Kruger, Ulf Simonsen, Mohamed Z. Nassef, Manfred Infanger and Daniela Grimm*
Affiliation:
- Institute of Biomedicine, Pharmacology, Aarhus University, Aarhus,Denmark
Keywords: Pulmonary arterial hypertension, clinical trials, non-prostanoid IP2-receptor agonist, selexipag, prostacyclin analogues, headache.
Abstract: Background: This review focuses on the treatment of pulmonary arterial hypertension (PAH) with selexipag and compares its drug-related therapeutic effects with those of prostacyclin analogues.
Methods: We searched the relevant literature and summarized the current clinical trials concerning selexipag and PAH.
Results: With only few cases per million, PAH is a rare disease, but when untreated it can be life-threatening. PAH is linked to elevated levels of endothelin (ET-1) and decreased levels of nitric oxide (NO) and prostacyclin (PGI2). PAH-specific therapeutic approaches concentrate on these characteristics with drugs targeting the endothelin- receptor (e.g. bosentan), phosphodiesterase-5 (e.g. sildenafil) or the prostacyclin-receptor (e.g. treprostinil). Recently, the new drug selexipag acting as a non-prostanoid IP2-receptor agonist has been approved for PAH therapy. The active form of selexipag (ACT-333679) was designed by the help of a medicinal chemistry program and it was further modified by replacing the terminal carboxyl group with an N-acylsulfonamide group to form the more stable oral drug, selexipag. Selexipag has a high selectivity for the IP2-receptor and differs from conventional prostacyclin analogues in its chemical structure. In the GRIPHON trial selexipag was demonstrated to significantly improve the primary composite endpoint of death or complications related to PAH (hazard ratio 0.6, 99% confidence interval, 0.46 to 0.78; P < 0.001) as well as exercise capacity in the form of the 6-minute walk distance (12.0 m treatment effect, 99% confidence interval, 1 to 24; P = 0.003). However, no significant reduction in all-cause mortality was achieved. Selexipag has also shown promising results in combination therapy with phosphodiesterase-5 inhibitors (PDE-5i) and/or endothelin receptor antagonists (ERA). The most common adverse effects (AEs), associated with selexipag, are headache, diarrhea, jaw pain, and nausea. Nevertheless, Selexipag was generally well tolerated during the GRIPHON trial.
Conclusions: Selexipag is a valuable addition to PAH therapeutics especially by reducing the PAH-related hospitalizations and thus improving quality of life in PAH patients.
Export Options
About this article
Cite this article as:
Sorensen M. Louise , Wehland Markus , Kruger Marcus, Simonsen Ulf , Nassef Z. Mohamed, Infanger Manfred and Grimm Daniela *, A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension, Current Pharmaceutical Design 2017; 23 (34) . https://dx.doi.org/10.2174/1381612823666170908114227
DOI https://dx.doi.org/10.2174/1381612823666170908114227 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epigenetics in the Cerebrovascular System: Changing the Code without Altering the Sequence
Current Neurovascular Research Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases
Current Vascular Pharmacology Recent Applications of Grape Polyphenols in Foods, Beverages and Supplements
Recent Patents on Food, Nutrition & Agriculture Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews Development of Physical Disability in Older Adults
Current Aging Science What Restricts the Clinical Use of Nicotinic Acid?
Current Vascular Pharmacology Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Primary and Secondary Stroke Prevention with Antiplatelet Drugs
Current Pharmaceutical Design The Application of Proteomics in Neurology
Current Proteomics Sleep Disorders Research From 1945 to 2020: A Bibliometric Analysis
CNS & Neurological Disorders - Drug Targets Occurrence, Functions and Biological Significance of Arginine-Rich Proteins
Current Protein & Peptide Science Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews How to Measure Exercise Performance
Current Respiratory Medicine Reviews Cognitive Impairment and Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Apolipoprotein A5: Extracellular and Intracellular Roles in Triglyceride Metabolism
Current Drug Targets The Impact of Body Mass Index and Type 2 Diabetes on Breast Cancer: Current Therapeutic Measures of Prevention
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Graphical Abstracts:
Current Hypertension Reviews Prognostic Value of Copeptin in Chronic Kidney Disease: From General Population to End-Stage Renal Disease
Current Protein & Peptide Science Enhanced Both in vitro and in vivo Kinetics by SLNs Induced Transdermal System of Furosemide: A Novel Approach
Recent Patents on Drug Delivery & Formulation Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets